Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viramune ad draws FDA citation

Executive Summary

Boehringer Ingelheim will work with FDA before an Oct. 6 deadline to make appropriate revisions to a Viramune print ad campaign following receipt of a 1letter from agency's drug ad division. Letter references an ad showing a runner standing on a track and includes the tag lines "I am taking on tomorrow"; "The power to suppress viral load"; and "Generally well-tolerated." Below the claims appears a box with "Important Safety Information for Viramune" but that box omits important risk information and is difficult to read, FDA said. A "black box" warning in the HIV therapy's labeling was recently modified (2"The Pink Sheet" Feb. 2, 2004, In Brief). [Editor's note: Coverage of the FDA ad division's warning letter to BI regarding Atrovent and Combivent appears in 3"The Pink Sheet" DAILY]...

You may also be interested in...



Boehringer modifies Viramune warning

Boehringer Ingelheim will modify "black box" warning for HIV agent Viramune to highlight that women with CD4+ count >250 cells/mm receiving chronic treatment are at high risk for hepatotoxicity, company "Dear Doctor" letter says. Boehringer has previously modified the box warning to recommend that patients be monitored for hepatotoxicity during the first three to four months of therapy (1"The Pink Sheet" Nov. 13, 2000, p. 22)...

Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests

Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel